Biofourmis founder launches health LMM startup
Over a year after leaving biotechnology unicorn Biofourmis, ex-CEO and founder Kuldeep Singh Rajput recently announced that he set up a new health tech company focused on generative AI.
In a LinkedIn post, he shared that his newly founded startup, OutcomesAI, has partnered with SingHealth to deploy its large multi-modal model (LMM) called Glia,...
AI-backed remote monitoring and digital therapeutics company Biofourmis confirmed the company's cofounder Kuldeep Singh Rajput stepped down as its CEO just one month after the company laid off 120 employees worldwide, 48 of whom were in the U.S.
"He remains committed to providing support and advice to the company going forward," Biofourmis told MobiHealthNews in an email. "We thank Kuldeep for...
AI-backed remote monitoring and digital therapeutics company Biofourmis confirmed it laid off 120 employees worldwide, including 48 workers in the U.S.
The Boston-based company offers home care tools to help remotely monitor acute and post-acute patients, then alter a care team when a patient's condition changes from their personal baseline.
It also offers digital therapies, including a heart-...
Patient experience is a popular buzzword for healthcare, but health systems probably aren't investing enough in consumer preferences, said Dr. Maulik Majmudar, chief medical officer and cofounder of Biofourmis.
"If you look at what patients are used to in the real world in other parts of their lives around banking or hotel booking or airlines or grocery shopping – like everything in life – it's...
AI-backed remote monitoring and digital therapeutics company Biofourmis added another $20 million to its Series D round, bringing its raise to $320 million.
The extension funding comes from Intel Capital, the strategic investment division of chipmaker Intel. The company first announced its Series D in April, which boosted Biofourmis to unicorn status with a valuation of $1.3 billion.
Biofourmis...
AI-backed remote monitoring and digital therapeutics company Biofourmis raised a whopping $300 million in Series D funding, boosting the company to unicorn status with a valuation of $1.3 billion.
The round was led by General Atlantic, with participation from CVS Health and existing investors Openspace Ventures and EDBI. Biofourmis said the Series D brings its total raise to $445 million.
WHAT...
AI-enabled virtual care and remote monitoring company Biofourmis has launched a chronic condition-management service dubbed Biofourmis Care.
The new specialty care program currently focuses on heart failure, diabetes, hypertension, atrial fibrillation and lipid management.
Using a wearable sensor, patients are remotely monitored by virtual care teams. These teams work with the patient's existing...
Dr. Maulik Majmuda has joined Boston-based virtual care and digital therapeutics company Biofourmis as its chief medical officer, the company announced this week.
Prior to this new role, Majmudar served as medical office at Amazon, where he led the development and launch of Amazon Halo. He also completed a stint at Massachusetts General Hospital as an associate director of the Healthcare...
Biofourmis, a Boston-based predictive-care startup that's leaning more and more into digital therapeutics, has wrapped up $100 million in Series C financing. The raise was led by SoftBank Vision Fund 2, and also saw contributions from prior backers Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI.
With this major jump from last May's $35 million Series B, the company is now...
